Goldman Sachs recently hosted the "Healthcare CEOs Unscripted" conference, and our health care analyst Max Macaluso was particularly interested in the interview with Merck's (MRK +0.31%) CEO, Kenneth Frazier. Max discusses the three takeaways he thought were most important from the talk -- including Merck's business strategy compared to the high profile spinouts recently engineered by Abbott (ABT 0.53%) and Pfizer (PFE 1.31%) -- and also offers his 2013 outlook for Merck.
